Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Study of Toca 511 and Toca FC in Brain Cancer
NCT04327011Phase 1Terminated
- Sponsor
- Tocagen
- Start
- Feb 2011
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vocimagene amiretrorepvec in glioblastoma multiforme (GBM), astrocytoma and malignant glioma, sponsored by Tocagen. Primary endpoint: Long term safety follow up at 15 years. Started Feb 2011; status: terminated.
02
Drugs
vocimagene amiretrorepvec
03
Conditions
glioblastoma multiforme (GBM)astrocytomamalignant glioma
Beyond the preview
Go deeper on NCT04327011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327011.